Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
Financials (USD)
Sales 2021 | 4.21M | Sales 2022 | 12.69M | Capitalization | 165M |
---|---|---|---|---|---|
Net income 2021 | -65M | Net income 2022 | -75M | EV / Sales 2021 | 168 x |
Net cash position 2021 | 148M | Net cash position 2022 | 21.66M | EV / Sales 2022 | 11.3 x |
P/E ratio 2021 |
-10.8
x | P/E ratio 2022 |
-2.17
x | Employees | 200 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 87.9% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Maria Sullivan
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yuri Maricich
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 21-11-30 | |
Timothy A. Wicks
BRD | Director/Board Member | 58 | 22-06-13 |
Corey McCann
BRD | Director/Board Member | 45 | 21-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 17 M€ | +5.38% | - |
1st Jan change | Capi. | |
---|---|---|
0.00% | 142 | |
+44.48% | 55.07B | |
+44.42% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- PEARQ Stock